Meiji Seika acquires Japanese rights to Dong-A's udenafil for urology uses
This article was originally published in Scrip
Executive Summary
Meiji Seika Pharma has acquired exclusive rights to develop and commercialise in Japan Dong-A Pharmaceutical's phosphodiesterase-5 inhibitor udenafil for urological indications, with an initial focus on benign prostatic hyperplasia (BPH).